Opsona Therapeutics

Opsona Therapeutics
Founded1 January 2004 Edit this on Wikidata
Headquarters
Dublin Edit this on Wikidata
,
Republic of Ireland Edit this on Wikidata
Websitewww.opsona.com

Opsona Therapeutics was a drug development company specialising in the human immune system and new drugs and vaccines to prevent and treat autoimmune/inflammatory conditions, cancers and infectious diseases.[1][2][3]

Based in Ireland, Opsona was a spin-out from Trinity College Dublin (TCD).[4] Ireland is ranked highly in the world in immunology research, and TCD has been at the forefront of the field.[5]

Opsona's research was primarily focused on the role of Toll-like receptors (TLRs) and TLR signalling in human innate immunity. The company was founded in 2004 by three immunologists:

The company went into liquidation in 2019 after unsuccessful clinical trials, and failure to find a buyer for OPN-305.

Opsona's main investors were international and life-science focused:

  • Inventages Venture Capital (Bahamas)[9]
  • Seroba Bioventures (Ireland)
  • GenenFund (United States)
  • Enterprise Ireland (Ireland)[10]
  1. ^ "Ireland's got talent". Retrieved 27 February 2018.
  2. ^ "Sunday Business Post article". Retrieved 27 February 2018.
  3. ^ "Opsona Therapeutics Limited: Private Company Information - Bloomberg". investing.businessweek.com. Archived from the original on September 10, 2012. Retrieved 27 February 2018.
  4. ^ "Emerging finalist: Mark Heffernan Opsona Therapeutics". Retrieved 27 February 2018.
  5. ^ Times Higher Education Supplement - QS World University Rankings 2007
  6. ^ "Trinity team makes vaccine discovery". 4 May 2009. Retrieved 27 February 2018.
  7. ^ Dublin, [email protected], Trinity College. "Kingston Mills - Research : School of Biochemistry and Immunology : Trinity College Dublin, the University of Dublin, Ireland". www.tcd.ie. Retrieved 27 February 2018.{{cite web}}: CS1 maint: multiple names: authors list (link)
  8. ^ "Article on the Trinity College Dublin website". Retrieved 27 February 2018.
  9. ^ "Opsona Therapeutics Closes EUR18M Funding - FierceBiotech". www.fiercebiotech.com. Retrieved 27 February 2018.
  10. ^ "PR Newswire article". Retrieved 27 February 2018.